



November 3, 2008

MannKind to Present at the Rodman & Renshaw Annual Global Investment Conference

VALENCIA, Calif., Nov. 3 /PRNewswire-FirstCall/ -- MannKind Corporation (Nasdaq: MNKD), focused on discovering, developing and commercializing treatments for diabetes and cancer, announced today that it will present at the Rodman & Renshaw Annual Global Investment Conference on Monday, November 10, 2008 at 9:55 AM (EST) at the New York Palace Hotel in New York City.

Interested parties can access a link to the live web cast of the presentation in the Investor Relations section of the Company's website at <http://www.mannkindcorp.com>. A replay of the presentation will be available for 14 days.

About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. Its pipeline includes AFRESA[™], which has completed Phase 3 clinical trials, and MKC253, which is currently in phase 1 clinical trials. Both of these investigational products are being evaluated for their safety and efficacy in the treatment of diabetes. For more information on MannKind Corporation and its technology, visit <http://www.mannkindcorp.com>.

SOURCE MannKind Corporation

CONTACT: Matthew J. Pfeffer, Corporate Vice President and Chief Financial Officer, +1-661-295-4784, mpfeffer@mannkindcorp.com

Web site: <http://www.mannkindcorp.com>